Pheochromocytoma and Paraganglioma

Know More, Take Action

3 Unique Dimensions. 3 Actions to Take.

Tap on the bubbles
to find out more

Rare What is Pheo and Para?

Rare, but

Not Alone

Learn why connecting to a community of patients and specialized doctors matters

Distinct Symptoms and Treatment

Diverse The Genetics of Pheo and Para

A Diverse Set of

Cancer-Causing Genes

Learn how genetic testing can help identify family members at risk
Watch one person's
pheo story

The information on this site is not intended to make a diagnosis or to take the place of talking to a US healthcare professional.

This site is intended solely for US residents and is governed solely by US laws and government regulations.

© 2019 Progenics Pharmaceuticals, Inc. All rights reserved

Progenics' trademarks, registered or otherwise, are the property of Progenics Pharmaceuticals, Inc. All content of this website, including text, images, graphics, sound files, and their arrangement, belongs to Progenics and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites. Please see our Privacy Policy for additional information. While Progenics makes reasonable efforts to include accurate, up-to-date information on the site, Progenics makes no warranties or representations as to its accuracy.

References
  1. Lenders JWM, et al. J Clin Endocrinol Metab. 2014; 99(6):1915–1942.
  2. Lefebvre M, Foulkes WD. Curr Oncol. 2014;21(1):e8-e17.
  3. Gunawardane PTK, Grossman A. Adv Exp Med Biol. 2017;956:239-259.
  4. Whalen R, et al. J Urol. 1992;147(1):1-10.
  5. Scholz T, et al. J Clin Endocrinol Metab. 2007;92(4):1217-1225.
  6. Engelman K. Bull N Y Acad Med. 1969;45(9):851-858.
  7. Streby KA, et al. Pediatr Blood Cancer. 2015;62(5):5-11.
  8. Pandit-Taskar N, Modak S. J Nucl Med. 2017;58(9.2):39S-53S.
  9. Jimenez C, et al. Curr Oncol Rep. 2013;15:356-371.
  10. Eisenhofer G, et al. Endocr Relat Cancer. 2004;11:423-436.
  11. Ayala-Ramirez M, et al. J Clin Endocrinol Metab. 2011;96(3):717-725.
  12. Amar L, et al. Horm Metab Res. 2012;44(5):385-389.
  13. Kerr D. Oxford Textbook of Oncology; 2016.
  14. Martucci VL, Pacak K. Curr Probl Cancer. 2014;38(1):7-41.
  15. US Census Bureau. US and World Population Clock. https://www.census.gov/popclock/. Accessed April 1, 2019.
  16. Fishbein L. Hematol Oncol Clin North Am. 2016;30(1):135-150.
  17. American Cancer Society. Cancer Facts & Figures 2017; 2017.
  18. American Cancer Society. Cancer Facts & Figures 2019; 2019.
  19. Kirmani S, Young W. 2014.
  20. Beard CM, et al. Mayo Clin Proc. 1983;58(12):802-804.
  21. Baudin E, et al. Eur J Endocrinol. 2014;171(3):R111-R1122.
  22. Pacak K. J Clin Endocrinol Metab. 2007; 92(11):4069-4079.
  23. Phan A. Case-Based Discussion- Systemic Therapies for Advanced PHEO and PGL. In: European Society for Medical Oncology (ESMO) Congress 2014; September 26-30, 2014; Madrid, Spain.
  24. Zuber SM, et al. Endocrinol Metab Clin North Am. 2011;40(2):295-311.
  25. Erlic Z, Neumann HP. Hormones (Athens). 2009;8(1):29-38.
  26. Kantorovich V, Eisenhofer G, Pacak K. Ann N Y Acad Sci. 2009;1148:462-468.
  27. Messerli FH, et al. Am J Cardiol. 2007;99(9):1325-1329.
  28. Gruber LM, et al. J Clin Endocrinol Metab. 2019;104(5):1386-1393.
  29. Blanchet EM, et al. Front Oncol. 2012;1(58):1-9.
  30. Roman-Gonzalez A, Jimenez C. Curr Opin Endocrinol Diabetes Obes. 2017;24(3):174-183.
  31. Ajallé R, et al. Horm Metab Res. 2009;41(9):687-696.
  32. Scholten A, et al. J Clin Endocrinol Metab. 2013;98(2):581-591.
  33. NCI Dictionary of Cancer Terms. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed April 17, 2019.
  34. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Neuroendocrine and Adrenal Tumors V.1.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed March 7, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  35. Lloyd RV, et al. WHO Classification of Tumours of the Endocrine Organs. 4th ed. 2017.
  36. Asa SL, et al. J Clin Med. 2018;7(280):1-15.
  37. Fishbein L, et al. Ann Surg Oncol. 2013;20(5):1444-1450.
  38. Remacha L, et al. Am J Hum Genet. 2019;104:651-664.
  39. Eisenhofer G, et al. Clin Biochem Rev. 2017;38(2):69-100.
  40. Brito JP, et al. Clin Endocrinol (Oxf). 2015;82(3):338-345.

NP-US-AZ-0058